1. Scrip
  2. >>Therapy Areas
  3. >>Cardiovascular

Lilly/BI's Jardiance Scores A Win In Heart Failure Where Rivals Have Not

 
• By Jessica Merrill

A Phase III trial in heart failure with preserved ejection fraction showed a benefit, which could result in a broad heart failure label for the SGLT2 inhibitor.

Heart EKG
Jardiance showed a benefit in HFpEF in a Phase III trial • Source: Alamy

Eli Lilly and Company and Boehringer Ingelheim GmbH's diabetes treatment Jardiance (empagliflozin) may be poised for a broad heart failure indication after the drug showed a statistically significant benefit in a Phase III trial in a setting where Novartis AG's heart failure drug Entresto (sacubitril/valsartan) and other rivals have not.

The companies announced positive top-line data on 6 July from a Phase III trial, EMPEROR-Preserved

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Cardiovascular

More from Therapy Areas

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

Multiple Launches Help Lilly’s Japan Growth

 
• By Ian Haydock

Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.

Novo Nordisk Looks To Septerna For Oral Obesity Options

 
• By Mary Jo Laffler

Deal Snapshot: The Danish drugmaker is partnering with GPCR drug discovery expert Septerna to develop multiple small molecules for cardiometabolic targets.